Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025
Alpha Cognition (NASDAQ:ACOG) reported significant progress in Q2 2025, marking its first full quarter of ZUNVEYL庐 commercialization. The company achieved ~$2M YTD net product revenue, with the drug being ordered in over 300 long-term care facilities and maintaining a 65% repeat order rate.
Key developments include securing a national Medicare Part D contract without prior authorization requirements, and China Medical System's New Drug Application (NDA) acceptance by NMPA. Additionally, the company completed a Department of Defense-funded Bomb Blast study demonstrating ALPHA-1062's efficacy in reducing neuroinflammation and toxic Tau proteins in mild traumatic brain injury (mTBI).
Alpha Cognition (NASDAQ:ACOG) ha riportato progressi significativi nel secondo trimestre 2025, segnando il suo primo trimestre completo di commercializzazione di ZUNVEYL庐. L'azienda ha raggiunto circa 2 milioni di dollari di ricavi netti da prodotto YTD, con il farmaco ordinato in oltre 300 strutture per assistenza a lungo termine e un tasso di riordino del 65%.
Tra gli sviluppi principali: l'aggiudicazione di un contratto nazionale Medicare Parte D senza requisiti di autorizzazione preventiva, e l'accettazione della New Drug Application (NDA) di China Medical System da parte della NMPA. Inoltre, 猫 stato completato uno studio finanziato dal Dipartimento della Difesa sul Bomb Blast che ha dimostrato l'efficacia di ALPHA-1062 nel ridurre la neuroinfiammazione e le proteine Tau tossiche in caso di trauma cranico lieve (mTBI).
Alpha Cognition (NASDAQ:ACOG) inform贸 avances significativos en el segundo trimestre de 2025, marcando su primer trimestre completo de comercializaci贸n de ZUNVEYL庐. La compa帽铆a alcanz贸 aprox. $2M de ingresos netos por producto YTD, con el f谩rmaco pedido en m谩s de 300 centros de cuidados a largo plazo y una tasa de reorden del 65%.
Los hitos clave incluyen la obtenci贸n de un contrato nacional Medicare Parte D sin requisitos de autorizaci贸n previa, y la aceptaci贸n por la NMPA de la New Drug Application (NDA) de China Medical System. Adem谩s, se complet贸 un estudio financiado por el Departamento de Defensa sobre explosiones (Bomb Blast) que demostr贸 la eficacia de ALPHA-1062 para reducir la neuroinflamaci贸n y las prote铆nas Tau t贸xicas en lesiones cerebrales traum谩ticas leves (mTBI).
Alpha Cognition (NASDAQ:ACOG)電� 2025雲� 2攵勱赴鞐� 鞙犾潣氙疙暅 歆勳爠鞚� 氤搓碃頄堨溂氅�, ZUNVEYL庐鞚� 觳� 氩堨Ц 鞝勳泊 靸侅梾頇� 攵勱赴毳� 旮半頄堨姷雼堧嫟. 須岇偓電� 鞐办磮 雽�牍� 鞎� 200毵� 雼煬鞚� 靾滌牅頀� 毵れ稖(YTD)鞚� 雼劚頄堨溂氅�, 頃措嫻 鞎诫鞚� 300瓿� 鞚挫儊鞚� 鞛リ赴 鞖旍枒鞁滌劋鞐愳劀 欤茧霅橃棃瓿� 鞛＜氍胳湪鞚� 65%毳� 鞙犾頄堨姷雼堧嫟.
欤检殧 靹标臣搿滊姅 靷爠 鞀轨澑 鞖旉惮 鞐嗢澊 甑皜鞝� Medicare 韺岉姼 D 瓿勳暯鞚� 頇曤炒頃� 鞝愱臣 China Medical System鞚� 鞁犾暯 項堦皜 鞁犾箔(NDA)鞚� NMPA鞐� 鞝戩垬霅� 鞝愳澊 鞛堨姷雼堧嫟. 霕愴暅 甑癌攵� 鞛愱笀 歆�鞗愳溂搿� 靾橅枆霅� 韽皽(Bomb Blast) 鞐瓣惮毳� 鞕勲頄堨溂氅�, 鞚� 鞐瓣惮電� 瓴诫頃� 鞕胳儊靹� 雵岇啇靸�(mTBI)鞐愳劀 ALPHA-1062臧� 鞁犼步鞐检瓿� 鞙犿暣頃� 韮�鞖� 雼氨歆堨潉 臧愳唽鞁滍偆電� 須臣毳� 氤挫棳欤检棃鞀惦媹雼�.
Alpha Cognition (NASDAQ:ACOG) a annonc茅 des progr猫s significatifs au 2e trimestre 2025, marquant son premier trimestre complet de commercialisation de ZUNVEYL庐. La soci茅t茅 a r茅alis茅 environ 2 M$ de chiffre d'affaires net produit YTD, le m茅dicament ayant 茅t茅 command茅 dans plus de 300 茅tablissements de soins de longue dur茅e et affichant un taux de r茅approvisionnement de 65 %.
Parmi les avanc茅es cl茅s : l'obtention d'un contrat national Medicare Part D sans exigence d'autorisation pr茅alable, et l'acceptation par la NMPA de la New Drug Application (NDA) de China Medical System. De plus, une 茅tude 芦 Bomb Blast 禄 financ茅e par le d茅partement de la D茅fense a 茅t茅 men茅e 脿 terme, d茅montrant l'efficacit茅 d'ALPHA-1062 dans la r茅duction de la neuroinflammation et des prot茅ines Tau toxiques en cas de traumatisme cr芒nien l茅ger (mTBI).
Alpha Cognition (NASDAQ:ACOG) meldete im zweiten Quartal 2025 deutliche Fortschritte und verzeichnete das erste vollst盲ndige Quartal der Kommerzialisierung von ZUNVEYL庐. Das Unternehmen erzielte rd. 2 Mio. USD Nettoproduktumsatz YTD, das Medikament wurde in 眉ber 300 Pflegeeinrichtungen bestellt und verzeichnete eine Wiederbestellquote von 65%.
Wesentliche Entwicklungen umfassen den Abschluss eines nationalen Medicare Part D-Vertrags ohne Anforderungen an vorherige Genehmigungen sowie die Annahme der New Drug Application (NDA) von China Medical System durch die NMPA. Dar眉ber hinaus wurde eine vom Verteidigungsministerium finanzierte Bomb-Blast-Studie abgeschlossen, die zeigte, dass ALPHA-1062 bei leichter traumatischer Hirnverletzung (mTBI) Neuroinflammation und toxische Tau-Proteine reduziert.
- Generated ~$2M YTD net product revenue from ZUNVEYL
- Achieved 65% repeat order rate across 300+ long-term care facilities
- Secured national Medicare Part D contract with no prior authorization required
- NDA acceptance in China opens potential for expansion into five new markets
- Positive DoD-funded study results for ALPHA-1062 in mTBI treatment
- Early stage of commercialization with limited revenue base
- Heavy dependence on successful market penetration in long-term care segment
Dallas, Texas--(Newsfile Corp. - August 15, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition advanced its first full quarter of ZUNVEYL® commercialization in 2Q25, driving meaningful early adoption in the U.S. long-term care (LTC) market and securing a key regulatory milestone in China. By quarter-end, ZUNVEYL (benzgalantamine) had been ordered in over 300 LTC facilities across priority regions, with
To view the full announcement, including downloadable images, bios, and more, .
Key Takeaways:
- First full quarter of ZUNVEYL® commercialization generated ~
$2M YTD net product revenue, with orders in 300+ nursing homes and65% repeat ordering. - China Medical System's NDA for ZUNVEYL accepted by the NMPA, paving the way for potential China approval and additional filings in four other countries by year-end.
- Completed DoD-funded Bomb Blast study showing ALPHA-1062 reduced neuroinflammation and toxic Tau proteins in mTBI, supporting further development.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
[email protected]
Source:
To view the source version of this press release, please visit
FAQ
What were Alpha Cognition's (ACOG) Q2 2025 ZUNVEYL sales results?
How is ZUNVEYL's market adoption progressing in the US?
What regulatory progress has Alpha Cognition made in China?
What were the results of Alpha Cognition's DoD-funded Bomb Blast study?
What insurance coverage progress has ZUNVEYL achieved?
